Trillium Therapeutics Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Trillium is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Our two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
No news available
This Month Only
Exclusive offer for our readers - unlock premium screeners, deep financials, and advanced analytics for 30 days, on us.
Discount code RYAN: Get 10% off if you continue after your free trial.
Claim free monthSponsored partner offer: After the trial, the plan converts to a discounted annual plan. Terms apply.